References
- Cross NC, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29(5):999–1003.
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
- Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20(11):1925–1930.
- Cross NC, White HE, Müller MC, et al. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172–2175.
- Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318–2357.
- Ferrand C, Deschamps M, Levitas A, et al. Xpert® BCR-ABL ultra, a high sensitivity assay, demonstrates a limit of detection reaching MR4.5 and below. Blood. 2017;130(Suppl 1):1610.
- Jobbagy Z, van Atta R, Murphy KM, et al. Evaluation of the Cepheid GeneXpert BCR-ABL assay. J Mol Diagn. 2007;9(2):220–227.
- Mahaffey V, Amar S, Day G-J, et al. Development of sample preparation procedures for testing specimens with high white blood cell counts for Xpert® BCR-ABL Ultra¥. Blood. 2018;132(Suppl 1):5444.
- López-Jorge CE, Gómez-Casares MT, Jiménez-Velasco A, et al. Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns. Ann Hematol. 2012;91(8):1245–1250.
- Winn-Deen ES, Helton B, Van Atta R, et al. Development of an integrated assay for detection of BCR-ABL RNA. Clin Chem. 2007;53(9):1593–1600. Sep
- Alikian M, Whale AS, Akiki S, et al. RT-qPCR and RT-Digital PCR: a comparison of different platforms for the evaluation of residual disease in chronic myeloid leukemia. Clin Chem. 2017;63(2):525–531.
- Bernardi S, Malagola M, Zanaglio C, et al. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med. 2019;8(5):2041–2055.
- Jennings LJ, George D, Czech J, et al. Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. J Mol Diagn. 2014;16(2):174–179.
- Maier J, Lange T, Cross M, et al. Optimized digital droplet PCR for BCR-ABL. J Mol Diagn. 2019;21(1):27–37.
- Wang WJ, Zheng CF, Liu Z, et al. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: a high sensitive method of the minimal residual disease and disease progression. Eur J Haematol. 2018;101(3):291–296.